Population studies examining the prevalence of venous disease have consistently produced findings that surprise both the general public and many healthcare professionals. The scale of venous insufficiency in the adult population — estimated to affect between twenty and forty percent of adults to some degree globally — makes it one of the most prevalent chronic conditions in the world. Yet the gap between this epidemiological prevalence and the number of patients actually diagnosed and receiving treatment is enormous, reflecting a massive reservoir of unrecognized, unmanaged venous disease in the community.
The reasons for this diagnostic gap are multifactorial and interrelated. Venous disease at its early stages is asymptomatic, meaning that patients have no subjective reason to seek evaluation. When symptoms do develop, they are typically mild and easily attributed to other causes — fatigue, aging, or lifestyle factors — that seem more plausible to most patients than vascular disease. Healthcare systems historically focused on acute and life-threatening conditions have allocated limited resources to the systematic identification of venous disease in the asymptomatic or mildly symptomatic population.
The clinical impact of this diagnostic gap is substantial. For every patient currently receiving treatment for venous ulceration — the most advanced and costly manifestation of venous disease — there are many more patients in the community whose disease has not yet progressed to that stage but whose disease trajectory will produce ulceration without intervention. The majority of these patients could be effectively treated at their current stage with straightforward interventions, preventing the progression that makes later-stage disease so much more difficult and costly to manage.
Screening programs for venous disease — systematic assessment of at-risk populations regardless of current symptom burden — offer a potential strategy for closing this diagnostic gap. Several models for venous screening have been proposed and piloted, ranging from opportunistic assessment during primary care visits to dedicated community vascular assessment programs. The evidence base for population-level venous screening is less developed than for conditions like hypertension or diabetes, but the burden of disease and the availability of effective treatment make this an area of active investigation.
Raising public awareness of venous disease — its prevalence, its symptoms, its consequences, and the availability of effective treatment — represents the most immediately scalable strategy for improving the detection rate of this underdiagnosed condition. Patients who understand that their leg symptoms might reflect venous disease, who know that effective treatment is available, and who feel empowered to seek evaluation rather than normalizing their symptoms are more likely to present at the stage when treatment can prevent the most serious complications. Education is the most accessible entry point into better venous disease detection.
